Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether carboplatin-paclitaxel-bevacizumab results
in a prolonged progression free survival compared to cisplatin-pemetrexed as first line
treatment in patients with KRAS mutated non-small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Dutch Society of Physicians for Pulmonology and Tuberculosis